BTIG initiated coverage of Misonix (NASDAQ:MSON) with a “buy” rating and $29 price target. The stock closed at $23.96 on June 11.

Ladenburg Thalmann raised its price target for Achieve Life Sciences (NASDAQ:ACHV) to $20 from $12 after the company reported statistically significant top-line results from its Phase 2 trial ORCA-1, which enrolled 254...

Roth Capital Partners initiated coverage of CRISPR Therapeutics PLC (NASDAQ:CRSP) with a “buy” rating and $50 price target. The stock closed at $44.38, up $1.50, on June 10.

H.C. Wainwright upgraded Sesen Bio (NASDAQ:SESN) to “buy” from “neutral” and raised its price target to $3 from $1 after the company had a successful Type B pre-biologics license application (BLA) meeting with FDA for...

Roth Capital Partners launched coverage of Intellia Therapeutics (NASDAQ:NTLA) with a “neutral” rating and $16 price target, saying the stock is fully valued ahead of first-in-human studies. The stock closed at $14.36...